MultiplexDX is proud to announce the publication of our manuscript titled “The Spatially Informed mFISHseq Assay Resolves Biomarker Discordance and Predicts Treatment Response in Breast Cancer,” now featured in Nature Communications. This study introduces our innovative mFISHseq platform, which addresses critical challenges in breast cancer biology by providing a more accurate approach for predicting treatment responses.

Current assays often struggle to capture the complexity of breast cancer and predict treatment outcomes. In our research, conducted on 1,082 breast tissue samples, we developed and validated mFISHseq, a novel technique that combines RNA-FISH with RNA sequencing, guided by laser capture microdissection. This approach ensures tumor purity, unbiased transcriptome profiling, and measures intratumoral heterogeneity. Our findings show that mFISHseq has 93% accuracy compared to immunohistochemistry (IHC) and provides both early and late prognostic information. We identified high-risk patients with immune signatures predictive of response to neoadjuvant immunotherapy in the I-SPY2 trial. Additionally, mFISHseq showed promise in identifying patients who may respond to antibody-drug conjugates (ADCs), including those validated by a 19-feature T-DM1 classifier. This study also illustrates the clinical feasibility of mFISHseq, deployed as a research-use only test in 48 patients, offering valuable insights into the efficacy of targeted therapies, including CDK4/6 inhibitors, immunotherapies, and ADCs. We are excited to contribute to the ongoing advancement of personalized breast cancer treatment and look forward to the continued impact of mFISHseq on clinical practice.

This achievment results from the dedication and collaboration of a multidisciplinary team of scientists and clinicians. By combining expertise in genomics, cancer biology, and spatial analytics, they have paved the way for a transformative tool that holds the potential to improve outcomes for breast cancer patients worldwide. We extend our deepest gratitude to the authors for their groundbreaking contributions. Your vision and innovation are shaping the future of oncology and precision medicine. 

For more information on our work, please read the full manuscript here: The Spatially Informed mFISHseq Assay Resolves Biomarker Discordance and Predicts Treatment Response in Breast Cancer.